Compare ArcelorMittal SA (MT) vs Summit Therapeutics Inc (SMMT) Price & Performance

ArcelorMittal (MT) trades at $61.30, down 1.64% on the day, with a bearish technical outlook despite recent earnings beats. The company shows mixed fundamentals with declining revenue trends from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent news highlights operational challenges including a $1B impairment charge from Ukrainian plant closures due to missile strikes, while analyst consensus remains positive with a $74.33 price target.

The stock presents a value opportunity with attractive valuation ratios (P/S 0.75, P/B 0.84) and strong analyst support (52% buy ratings), but faces significant operational risks from geopolitical exposure and declining cash flow trends. Near-term performance depends on European demand recovery and successful execution of growth projects amid industry headwinds.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.